Scenic joins LITE program to test Parkinson’s treatment approach
Scenic Biotech has joined the LRRK2 Investigative Therapeutics Exchange (LITE) program to study its PLA2G15 inhibitors as a potential treatment approach for Parkinson’s disease, including in people…